Europe CAR T-Cell Therapy Market (2026-2031)
The Europe CAR T-Cell Therapy Market was valued at $191.7 Million in 2026 and projected to reach to $324 Million by 2031, representing a compound annual growth rate of 11.1%. Europe's CAR T-Cell Therapy Market is poised for sustained expansion through 2031, driven by increasing clinical adoption, favorable regulatory environments, and rising healthcare expenditure on oncology.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Europe CAR T-Cell Therapy Market Trends and Insights
- Europe represents a significant regional hub for advanced immunotherapy adoption, driven by robust healthcare infrastructure, regulatory frameworks, and increasing investment in precision medicine.
- The region's market growth is supported by rising prevalence of hematologic malignancies and growing clinical adoption across major European healthcare systems. During the 2026–2031 forecast period, Europe will experience accelerated market expansion fueled by expanded patient access programs, reimbursement improvements, and manufacturing capacity enhancements.
- Europe's competitive landscape includes both established biopharmaceutical players and emerging CAR T developers, positioning the region as a key growth market alongside North America.
- Regulatory harmonization through the European Medicines Agency (EMA) continues to streamline approval pathways, enabling faster market entry for innovative CAR T therapies across Europe..
Key Market Statistics
- CAGR (2026-2031) 11.1% CAGR
- Market Size, 2026 ~USD 191.7 Million
- Forecast, 2031 ~USD 324 Million
- Geography Europe
Europe CAR T-Cell Therapy Market Overview
Market Valuation & Growth :
Europe's CAR T-Cell Therapy Market is valued at $191.7 million in 2026 and is projected to reach $324.0 million by 2031, demonstrating an 11.1% CAGR. This growth trajectory reflects strong regional adoption of advanced immunotherapy solutions.
Healthcare Infrastructure Leadership :
Europe benefits from world-class healthcare systems, established regulatory pathways through the EMA, and significant public and private investment in precision medicine. These factors position the region as a key hub for CAR T-Cell Therapy development and commercialization.
Germany & UK Market Dominance :
Germany leads European adoption with $1,089.3 million in market size, followed by the UK at $910.7 million. These markets drive innovation and set clinical standards across the continent, attracting major pharmaceutical and biotech investments.
Regulatory & Reimbursement Support :
European regulatory frameworks and growing reimbursement coverage for CAR T-Cell therapies are accelerating market penetration. Harmonized approval processes and health economic evidence support broader patient access across member states.
Europe CAR T-Cell Therapy Market Dynamics
- The region's mature healthcare infrastructure and strong emphasis on precision medicine create ideal conditions for advanced immunotherapy deployment.
- Germany and the UK will continue to lead market growth, while emerging markets within Europe present untapped opportunities for expansion. Key growth catalysts include expanding approved indications, improved manufacturing capabilities, and enhanced patient access programs.
- European healthcare systems' commitment to innovative cancer treatments, combined with growing awareness among oncologists and patients, will support market penetration.
- Strategic partnerships between regional biotech firms and global leaders will further accelerate commercialization and market consolidation through 2031..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Merck KGaA
- Thermo Fisher Scientific Inc.
- SANOFI
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- Europe's CAR T-Cell Therapy Market will grow from $191.7M (2026) to $324.0M (2031) at an 11.1% CAGR.
- Europe benefits from advanced healthcare infrastructure and EMA regulatory support, accelerating therapy adoption.
- Rising hematologic malignancy prevalence and improved reimbursement policies drive market expansion across Europe.
- Europe's competitive landscape attracts both multinational and emerging CAR T developers, intensifying innovation.
CAR T-Cell Therapy Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | CD19/20 (Target) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 13.7% from 2026 to 2031 |
| Largest Segment | CD19 (Target) |
| Market Size Base Year (Billions) | ~USD 7.25 (2026) |
| Revenue Forecast (Billions) | ~USD 13.78 (2031) |
| Segments Covered | Product, Target, Indication |
Europe CAR T-Cell Therapy Market Report Segmentation
3 segment dimensions are covered across the global market.
By Product
- Abecma
- Breyanzi
- Carvykti
- Kymriah
- Other Products
- Tecartus
- Yescarta
By Target
- Bcma
- Cd19
- Cd19/20
- Cd7
- Other Targets
By Indication
- Acute Lymphoblastic Leukemia (All)
- B-Cell Lymphoma (Bcl)
- Multiple Myeloma
- Other Indications
EUROPE: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| HOSPITALS | 841.79 | 1107.03 | 1236.04 | 1372.81 | 1527.67 | 1706.68 | 1912.31 | 2149.93 | 11.7 |
| LONG-TERM CARE FACILITIES | 54.8 | 71.14 | 75.52 | 79.56 | 83.76 | 88.28 | 93.02 | 98 | 5.4 |
| SPECIALTY CENTERS | 430.85 | 563.47 | 626.61 | 693.17 | 768.3 | 854.92 | 954.13 | 1068.46 | 11.3 |
| TOTAL | 1327.45 | 1741.64 | 1938.17 | 2145.54 | 2379.73 | 2649.88 | 2959.47 | 3316.39 | 11.3 |
REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| HOSPITALS | 129.1 | 175.5 | 191.2 | 208.2 | 227.1 | 248.1 | 271.6 | 297.9 | 9.3 |
| LONG-TERM CARE FACILITIES | 7.8 | 10.4 | 10.7 | 11 | 11.3 | 11.6 | 11.8 | 12.1 | 2.4 |
| SPECIALTY CENTERS | 67.2 | 90.8 | 98.6 | 107 | 116.2 | 126.5 | 137.9 | 150.7 | 8.8 |
| TOTAL | 204.05 | 276.72 | 300.61 | 326.25 | 354.59 | 386.19 | 421.34 | 460.57 | 8.9 |
Target Audience
- Pharmaceutical & Biotech Companies : Develop market entry strategies, assess competitive positioning, and identify partnership opportunities across European markets. Understand regional regulatory requirements and reimbursement landscapes for CAR T-Cell therapies.
- Healthcare Investors & PE Firms : Evaluate investment opportunities in European CAR T-Cell therapy companies and healthcare infrastructure. Assess market growth potential, competitive dynamics, and exit opportunities in high-growth regional markets.
- Hospital & Healthcare Systems : Plan CAR T-Cell therapy program development, assess patient demand, and understand clinical adoption trends. Benchmark against peer institutions and optimize resource allocation for immunotherapy services.
- Medical Device & Diagnostic Companies : Identify complementary product opportunities and partnership potential within Europe's CAR T-Cell ecosystem. Understand clinical workflows and integration points for diagnostic and monitoring solutions.
- Government & Regulatory Bodies : Develop evidence-based healthcare policies, assess market trends, and understand reimbursement implications. Support informed decision-making on precision medicine funding and regulatory framework development.
Key Companies in the Europe CAR T-Cell Therapy Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| JOHNSON & JOHNSON | United States | Public Company | Oncology and Immunology (Innovative Medicine),Neuroscience, Cardiovascular & Metabolism, Pulmonary Hypertension, Infectious Diseases,Surgery and Interventional (instrumentation, energy, stapling, wound closure, biosurgery, robotic and digital), |
| GILEAD SCIENCES, INC. | United States | Public Company | HIV portfolio (Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, Yeztugo),Liver disease and other antivirals (Epclusa, Livdelzi, Vemlidy, AmBisome),COVID-19 (Veklury), |
| BRISTOL-MYERS SQUIBB COMPANY | United States | Public Company | Eliquis (anticoagulation),Immuno-oncology (Opdivo, Yervoy, Opdualag, Opdivo Qvantig),Hematology (Revlimid, Pomalyst/Imnovid, Reblozyl, Abecma, Breyanzi), |
| NOVARTIS AG | Switzerland | Public Company | Oncology & Hematology (Kisqali, Tafinlar+Mekinist, Jakavi, Pluvicto, Lutathera, Scemblix, Fabhalta),Immunology & Neuroscience (Cosentyx, Xolair, Ilaris, neurology assets),Cardiovascular, Renal & Metabolic (Entresto, Leqvio, other CVRM), |
| AUTOLUS THERAPEUTICS | United Kingdom | Public Company | CD19 CAR-T franchise (AUCATZYL / obe-cel – oncology),Autoimmune CD19 programs (obe-cel in SLE, MS, lupus nephritis),Next-generation oncology pipeline (AUTO1/22, AUTO8, AUTO6NG), |
| JW (CAYMAN) THERAPEUTICS CO., LTD. | China | Public Company | Commercial and late-stage CAR-T for hematologic malignancies (Carteyva, JWCAR201, JWCAR239),Autoimmune indications (relma-cel for SLE and related programs),Solid tumor pipeline (JWATM204/214/203/213, JWTCR001, JWCAR031), |
| CARSGEN THERAPEUTICS HOLDINGS LIMITED | China | Public Company | Zevor-cel (CT053) – BCMA CAR-T for R/R multiple myeloma,Autologous solid-tumor CAR-T (CT041, CT011, CT071, CT0590/CT0596),Autoimmune and B-cell malignancy pipeline (KJ-C2219, KJ-C2320, KJ-C2529), |
| CARTESIAN THERAPEUTICS, INC. | United States | Public Company | Descartes-08 (autoimmune and rare pediatric indications),Descartes-15 (multiple myeloma),Platform and other mRNA cell therapy programs/services, |
| LYELL IMMUNOPHARMA, INC. | United States | Public Company | Hematologic CAR T programs (ronde-cel and platform),Solid tumor CAR T programs (LYL273 and related),Platform technologies and enabling IP (c-Jun, NR4A3 KO, Epi-R, CD62L enrichment), |
JOHNSON & JOHNSON
Johnson & Johnson is a diversified healthcare company founded in 1886 and headquartered in the United States. With 138,200 employees, it operates as a public company serving global markets.
GILEAD SCIENCES, INC.
Gilead Sciences, Inc. is a United States-based biopharmaceutical company founded in 1987. The public company employs 17,000 people and focuses on developing innovative therapeutics.
BRISTOL-MYERS SQUIBB COMPANY
Bristol-Myers Squibb Company is a pharmaceutical company established in 1887 in the United States. As a public company with 32,500 employees, it develops and manufactures pharmaceutical products.
NOVARTIS AG
Novartis AG is a Swiss multinational pharmaceutical company founded in 1996. The public company employs 75,267 people and operates globally in the healthcare sector.
AUTOLUS THERAPEUTICS
Autolus Therapeutics is a United Kingdom-based biopharmaceutical company founded in 2014. The public company has 753 employees and focuses on cell therapy development.
JW (CAYMAN) THERAPEUTICS CO., LTD.
JW (Cayman) Therapeutics Co., Ltd. is a China-based pharmaceutical company founded in 2016. The public company employs 314 people and operates in the therapeutic development sector.
CARSGEN THERAPEUTICS HOLDINGS LIMITED
Carsgen Therapeutics Holdings Limited is a China-based biopharmaceutical company founded in 2014. The public company has 355 employees and specializes in cell therapy development.
CARTESIAN THERAPEUTICS, INC.
Cartesian Therapeutics, Inc. is a United States-based public biopharmaceutical company with 75 employees. The company specializes in cell therapy and therapeutic development.
LYELL IMMUNOPHARMA, INC.
Lyell Immunopharma, Inc. is a United States-based public immunotherapy company founded in 2018. The company has 161 employees and develops cell-based immunotherapies.
Countries within Europe - compare and drill down
| Country | 2025 size (native) |
|---|---|
| Germany | USD 1089.3 Million |
| UK | USD 910.7 Million |
| France | USD 58.2 Million |
| Italy | USD 18.7 Million |
| Spain | USD 11.9 Million |
| Rest Of Europe | USD 33.3 Million |
Country market size visualization
Reasons to Buy this Report
- Regional Market Segmentation : Gain detailed insights into Europe's CAR T-Cell Therapy Market with country-level breakdowns for Germany, UK, France, Italy, Spain, and Rest of Europe. Understand market dynamics specific to each region's healthcare system and regulatory environment.
- Competitive Landscape Intelligence : Identify leading players, market consolidation trends, and competitive positioning across European markets. Benchmark your strategy against regional competitors and understand market share distribution among key stakeholders.
- Growth Opportunity Assessment : Evaluate emerging opportunities in underserved European markets and identify high-growth segments. Assess reimbursement trends, clinical adoption rates, and unmet patient needs driving market expansion through 2031.
- Regulatory & Reimbursement Insights : Navigate Europe's complex regulatory landscape with detailed analysis of EMA approval pathways, national reimbursement policies, and health economic requirements. Understand market access strategies for different European countries.
- Strategic Investment Guidance : Make informed investment and partnership decisions with comprehensive market forecasts, growth projections, and risk assessments. Identify optimal entry points and expansion strategies for European market penetration.
Frequently asked questions
What is the projected market size for CAR T-Cell Therapy in Europe by 2031?
Europe's CAR T-Cell Therapy Market is projected to reach $324.0 million by 2031, up from $191.7 million in 2026.
What is the CAGR for CAR T-Cell Therapy in Europe from 2026 to 2031?
Europe's CAR T-Cell Therapy Market is expected to grow at a compound annual growth rate (CAGR) of 11.1% during the 2026–2031 forecast period.
What factors are driving CAR T-Cell Therapy adoption in Europe?
Key drivers include rising hematologic malignancy prevalence, robust healthcare infrastructure, EMA regulatory support, improved reimbursement policies, and increased investment in precision medicine across Europe.
How does Europe's CAR T-Cell Therapy market compare to other regions?
Europe represents a significant regional market with an 11.1% CAGR, positioning it as a key growth hub alongside North America, supported by advanced healthcare systems and regulatory harmonization.
What role does the EMA play in Europe's CAR T-Cell Therapy market?
The European Medicines Agency (EMA) streamlines approval pathways and enables regulatory harmonization, facilitating faster market entry for innovative CAR T therapies across Europe.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current size of the CAR T-cell therapy market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), United States Food and Drug Administration (US FDA), American Society of Gene & Cell Therapy (ASGCT), European Medicines Agency (EMA), Industry Association of Synthetic Biology (IASB), International Society for Cell & Gene Therapy (ISCT), National Center for Complementary and Integrative Health (NCCIH), BioPharm International, ScienceDirect, News Articles, Journals, Press Releases, Paid Databases, Expert Interviews, and MarketsandMarkets Analysis, among others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information about major players, global product revenues, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data was collected and analyzed to arrive at the overall size of the global CAR T-cell therapy market, which was validated through primary research.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the CAR T-cell therapy market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
CAR T-Cell Therapy Market Size: Bottom-up Approach and Top-down Approach
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
CAR T-cell therapy is a treatment method wherein a patient’s T-cells (a type of immune system cell) undergo modification in a laboratory to target and attack cancer cells effectively. Initially, T-cells are extracted from the patient’s bloodstream. Then the gene for a special receptor that binds to a specific protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is known as a chimeric antigen receptor (CAR). Following this modification process, the CAR T-cells are cultured and multiplied in large quantities. Finally, the amplified CAR T-cells are administered to the patient via infusion. This therapeutic approach is predominantly utilized in the management of specific blood cancers, and ongoing research is exploring its potential applications in treating other forms of cancer. The CAR T-Cell therapy market includes approved and pipeline CAR T-cell products for therapeutic purposes.
Key Stakeholders
- Pharmaceutical Companies
- Biotechnology Companies
- Clinical Research Organizations (CROs)
- Regulatory Authorities
- Healthcare Providers
- Patients and Patient Advocacy Groups
- Investors and Venture Capital Firms
- Research & Development Companies
- Research Laboratories & Academic Institutes.
- Market Research & Consulting Firms
Report Objectives
- To define, describe, and forecast the CAR T-cell therapy market by value for product, target, indication, demographic, end user, and region
- To define, describe, and forecast the CAR T-cell therapy market by volume for the product segment at the global level
- To provide detailed information regarding the major drivers, restraints, opportunities, and challenges, influencing the market growth
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall CAR T-cell therapy market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
- To provide an overview of the market with specialized analysis such as trends/disruptions impacting customers’ business, pricing analysis, value/ supply chain analysis,ecosystem analysis, technology analysis, patent analysis, key conferences & events 2026-2027, regulatory landscape, Porter’s five forces analysis, key stakeholders and buying criteria, and investment and funding scenario
Available customizations:
- With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographic Analysis
- Further breakdown of the Rest of Europe CAR T-cell therapy market, by country
- Further breakdown of the Rest of Asia Pacific CAR T-cell therapy market, by count
Company Information
- Detailed analysis and profiling of additional market players (up to five
Segment Analysis
- Cross-segment analysis
Get the Full CAR T-Cell Therapy Market Report
Full forecast, segment splits, and company analysis for all CAR T-Cell Therapy Market.
- US CAR T-Cell Therapy Market
- Canada CAR T-Cell Therapy Market
- Germany CAR T-Cell Therapy Market
- UK CAR T-Cell Therapy Market
- France CAR T-Cell Therapy Market
- Italy CAR T-Cell Therapy Market
- Spain CAR T-Cell Therapy Market
- China CAR T-Cell Therapy Market
- Japan CAR T-Cell Therapy Market
- India CAR T-Cell Therapy Market
- Australia CAR T-Cell Therapy Market
- South Korea CAR T-Cell Therapy Market
- Brazil CAR T-Cell Therapy Market
- UAE CAR T-Cell Therapy Market
- Rest Of Europe CAR T-Cell Therapy Market
- Rest Of Asia Pacific CAR T-Cell Therapy Market
- Rest Of Latin America CAR T-Cell Therapy Market
- GCC Countries CAR T-Cell Therapy Market
- Rest Of Middle East CAR T-Cell Therapy Market
- Kingdom Of Saudi Arabia CAR T-Cell Therapy Market
- Rest Of GCC Countries CAR T-Cell Therapy Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report